Reuters logo
BRIEF-PCI Biotech granted orphan drug designation from FDA for Fimaporfin
October 4, 2017 / 4:23 PM / 14 days ago

BRIEF-PCI Biotech granted orphan drug designation from FDA for Fimaporfin

Oct 4 (Reuters) - Pci Biotech Holding Asa

* Says the U.S. food and drug administration (FDA) has granted Orphan drug designation to its lead product candidate, Fimaporfin, a drug that treats patients suffering from Cholangiocarcinoma (bile duct cancer)

* Says Orphan designation is a “significant regulatory milestone” and that it “supports further development of FimaChem in this indication and provides important development and commercialisation benefits” Source text for Eikon: Further company coverage: (Reporting By Joachim Dagenborg)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below